Markets:

Overview

News

Currencies

International

Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

7.160 +0.040 (+0.56%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 Next >

Intapp Posts Better-Than-Expected Earnings, Joins Sapiens International, Arcturus Therapeutics, Gildan Activewear And Other Big Stocks Moving Higher On Wednesday ↗

August 13, 2025

Via Benzinga

Mercury Systems Posts Better-Than-Expected Earnings, Joins Green Dot, Arcturus Therapeutics And Other Big Stocks Moving Higher On Tuesday ↗

August 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 12, 2025

Via Benzinga

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock ↗

March 07, 2025

Via Benzinga

Breaking Down Arcturus Therapeutics: 5 Analysts Share Their Views ↗

February 14, 2025

Via Benzinga

Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews ↗

January 28, 2025

Via Benzinga

Top movers in Tuesday's session ↗

August 12, 2025

Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Arcturus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

August 12, 2025

Via Benzinga

Expert Outlook: Arcturus Therapeutics Through The Eyes Of 5 Analysts ↗

July 02, 2025

Via Benzinga

Which stocks are moving before the opening bell on Tuesday? ↗

May 13, 2025

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Unveiling 3 Analyst Insights On Arcturus Therapeutics ↗

October 01, 2024

Via Benzinga

The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts ↗

March 11, 2024

Via Benzinga

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

Demystifying Arcturus Therapeutics: Insights From 7 Analyst Reviews ↗

May 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 13, 2025

Via Benzinga

Which stocks are moving after the closing bell on Monday? ↗

May 12, 2025

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses ↗

September 30, 2024

CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a...

Via Benzinga

Earnings Scheduled For March 6, 2025 ↗

March 06, 2025

Via Benzinga

ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 05, 2024

ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival ↗

June 25, 2024

Via Benzinga

Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M ↗

June 12, 2024

Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Video Communications Inc (NASDAQ:ZM).

Via Benzinga

Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness ↗

June 10, 2024

On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a...

Via Benzinga

Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst ↗

June 07, 2024

Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety .

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 07, 2024

Via Benzinga

Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic ↗

May 28, 2024

Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function.

Via Benzinga

Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

May 28, 2024

Via Benzinga

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 28, 2024

Via Benzinga

Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential' ↗

May 09, 2024

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

Via Benzinga

ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.